March 24, 2011 - 8:16 AM EDT
Print Email Article Font Down Font Up
Update on Signature Mapping TBDx Tuberculosis Test Clinical Trial
Update on Signature Mapping TBDx Tuberculosis Test Clinical Trial

Key points of the study currently underway are:

  • Performance of the TBDx system to date indicates that it performs best as an expert Decision Support System (DSS) to complement expertly trained digital microscopists, offering as additional benefits advances in productivity and lower costs of diagnosis.
  • A protocol change to accommodate the DSS approach to the use of TBDx, as well as requests from end-user test experts was approved and the study has recommenced.
  • Preliminary results suggest that TBDx may well be best placed as a 'front-end' screening technology before the use of newer but more expensive diagnostic technologies.
  • The study sample size was reduced to 1000 slides (from 2400) to speed up time to results and costs of processing.
  • A routine high-volume laboratory demonstration project protocol has already been developed to follow on from the main scientific study pending results from this study.
  • The results of the study are expected to start rolling out in April 2011.
  • If successful, this will be the world's first fully automatic TB diagnostic microscopy system and will establish the underlying Signature Mapping technology as a valid platform on which to develop a host of other image based disease diagnostics.

About Applied Visual Sciences, Inc.
Applied Visual Sciences, Inc. is the holding company and IT development organization for subsidiaries specializing in high-performance imaging analysis technologies and advanced analytics for automated recognition of targets of interest. Applied Visual Sciences' subsidiaries include Guardian Technologies International, Inc., a homeland security/defense technology entity, and Signature Mapping Medical Sciences, Inc., a healthcare technology entity. The company is quoted on the OTC Bulletin Board under the symbol APVS.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995:
Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, capital raising activities, trends in the markets, variations in the company's cash flow, competition, business development efforts, technology availability and cost of materials and other risk factors. Factors that could cause actual results to differ materially are discussed in the Company's most recent filings with the Securities and Exchange Commission.

CONTACT:

For Applied Visual Sciences:
Michael Trudnak
+1 703-464-5495

For Signature Mapping Medical Sciences
Richard Borrelli
+1 703-464-5495

For Media:
Julie Shepherd of Accentuate PR
+1 815-479-1833